跳转至内容
Merck
CN

Severe cholestatic jaundice associated with piroxicam.

Gastroenterology (1991-12-01)
K S Hepps, G M Maliha, R Estrada, R W Goodgame
摘要

A 62-year-old man with rheumatoid arthritis developed jaundice while taking piroxicam. A full evaluation including ultrasound, computerized tomography, endoscopic cholangiography, and liver biopsy confirmed the diagnosis of intrahepatic cholestasis. The patient's jaundice and all other liver function abnormalities normalized 4 months after he discontinued taking piroxicam. This is the first case report in the United States of severe liver toxicity associated with piroxicam. The six cases in the English-language literature are reviewed, featuring the presentation, patterns of liver injury, and outcome in each. Piroxicam should be considered as a potential cause of cholestatic jaundice when other more common etiologies have been excluded.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
吡罗昔康, ≥98% (TLC)
USP
吡罗昔康, United States Pharmacopeia (USP) Reference Standard
吡罗昔康, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
吡罗昔康, meets USP testing specifications
吡罗昔康, European Pharmacopoeia (EP) Reference Standard